Trump Administration Targets Pharmaceutical Ads in Major FDA Crackdown

What Happened

The Food and Drug Administration has announced a sweeping enforcement campaign against pharmaceutical companies that run misleading ads. Backed by the Trump administration, the FDA is targeting ads that exaggerate drug benefits, downplay risks, or fail to meet disclosure requirements.

The agency has already issued around one hundred cease-and-desist notices. It has also sent thousands of warning letters to pharmaceutical companies. The notices target what officials describe as deceptive marketing practices that have gone unchecked for too long.

At the heart of the crackdown is the elimination of what the FDA calls the ‘adequate provision’ loophole. This rule previously allowed drug makers to skip detailed safety information in ads. Instead, they could direct consumers to websites or toll-free numbers. The new guidance requires that risks and side effects be clearly presented within the ad itself. They can no longer be offloaded to a separate platform.

Social media is also in the FDA’s crosshairs. Drug companies and paid influencers must now follow the same standards as broadcast and print media. Posts that highlight benefits without acknowledging side effects or proper usage will be subject to enforcement.

Why It Matters

For years, the pharmaceutical industry has spent billions on ads that target consumers directly. The goal is to shape public perception, influence patient requests, and pressure doctors to prescribe specific brands. Critics have long said these ads are skewed toward sales rather than patient safety.

Bigger than DoorDash’s $79B Explosion?

When DoorDash first hit the scene, critics brushed it off as “nothing new.”

And here’s the kicker: they were right.

Yet the founders of this "delivery business” knew something that the rest of the world missed.

Today, DoorDash is worth $79 billion, with a valuation increase of 110,800% for early investors.

But there may be a second chance with a company that recently grew 32,481%.

No, it’s not a food delivery service…

It’s a company that rests at the intersection of three fast-growing global markets, driven by the same vision of turning personal assets into income streams.*

Mode Mobile is tapping into the earning potential of smartphones, and the results speak for themselves:

● Helped users earn and save more than $325 million
● ⁠$75M+ in revenue and growing.
● #1 in software on Deloitte's 2023 fastest-growing companies list.

There are over 8 billion smartphones and Mode has gained the support of over 50,000 investors.

Their last two rounds were oversubscribed at $0.30/share and only limited room remains in the current one.  

>>> Get all the details here

The FDA’s new push reflects growing concern that the current model allows too much manipulation. A thirty-second television spot or a polished Instagram post can oversell benefits. Fine print warnings or vague voiceovers do little to balance the message. Removing the ability to bury risk information behind links or disclaimers forces companies to present a more honest picture.

This crackdown also comes at a time when trust in pharmaceutical companies is low. The pandemic gave the industry renewed visibility but also deeper scrutiny. As new drugs enter the market quickly, clear and accurate communication is essential. It matters not only for informed choices but also for public health.

How It Affects Readers

For consumers, the change will be most noticeable in how pharmaceutical ads look and sound. Viewers and social media users will see ads that include direct information about side effects, usage restrictions, and warnings. They will no longer need to visit a website or read fine print to find this information. For example, television ads must now include meaningful risk disclosure as part of the main message.

It also means that companies and influencers can no longer gloss over key facts. If a medication carries serious risks, those risks must be communicated up front. This applies to television, social media, video platforms, and even podcasts. Any channel used to market drugs to the public must now follow the same standards.

The FDA’s actions may lead to fewer or more cautious ads in the short term. In the long term, it could reshape how companies approach marketing. Instead of focusing on emotional appeal, drug makers will need to design messages around clarity, accuracy, and compliance.

The enforcement campaign is already underway. More actions are expected in the months ahead. Legal challenges may follow, but the FDA has made its stance clear. Drug ads must tell the whole story, not just the part that sells.

*Mode Mobile recently received their ticker reservation with Nasdaq ($MODE), indicating an intent to IPO in the next 24 months. An intent to IPO is no guarantee that an actual IPO will occur.

The Deloitte rankings are based on submitted applications and public company database research, with winners selected based on their fiscal-year revenue growth percentage over a three-year period.

In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. Mode Mobile has filed a Form C with the Securities and Exchange Commission in connection with its offering, a copy of which may be obtained here: https://www.sec.gov/Archives/edgar/data/1748441/000164117225025402/ex99.pdf